Showing 1 - 20 results of 16,239 for search '(( 5 ((non decrease) OR (_ decrease)) ) OR ( _ ((largest decrease) OR (larger decrease)) ))', query time: 0.67s Refine Results
  1. 1

    The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. by Gui Araujo (22170819)

    Published 2025
    “…Parameter values: interaction strengths were drawn from a half-normal distribution of zero mean and a standard deviation of 0.2, and strength for consumers was made no larger than the strength for resources. Communities started with 5 non-interacting species. …”
  2. 2

    GO analysis of genes with decreased expression (<0.5) in <i>pab2</i>Δ. by Ziyue Liu (381532)

    Published 2025
    “…<p>GO analysis of genes with decreased expression (<0.5) in <i>pab2</i>Δ.</p>…”
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7

    Inhibition of NEAT1 decreased the miR-204-5p expression and increased Six1 expression. by Lei Li (29537)

    Published 2024
    “…<p>(A) NEAT1 expression following siRNA transfection in BEAS-2B cells; (B-D) The expression of NEAT1, miR-204-5p, and Six1 after decreasing NEAT1 expression. * p <0.05, *** p < 0.001, and **** p <0.0001.…”
  8. 8

    Validation of genetic markers for risk of OA or knee OA for decrease in minJSW. by Mieke L. M. Bentvelzen (21594442)

    Published 2025
    “…<p><b>(A)</b> Manhattan plot of minJSW decrease at 24 months. The Manhattan plots show the -log10(P) values of all ~ 1,5 million SNPs against their position. …”
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15

    Nineteen SNPs with significant association (<i>P < </i>5 × 10<sup>−8</sup>) with risk on minJSW decrease in knee OA. by Mieke L. M. Bentvelzen (21594442)

    Published 2025
    “…<p>Nineteen SNPs with significant association (<i>P < </i>5 × 10<sup>−8</sup>) with risk on minJSW decrease in knee OA.…”
  16. 16
  17. 17

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  18. 18
  19. 19
  20. 20